In his message to shareholders, K. Anji Reddy, said in the annual report (released here on Monday) that it was premature to share any details and information would be given as and when deals were finalised. Noting that despite reversals, the company actually raised R&D investments during 2004-05 by 41 per cent, he said this year would be a challenging one for the company. On corrective measures, he said the company was now more focussed on metabolic disorders, obesity, cardiovascular and cancer. It had separated potentially winning molecules and eliminated 'also rans (molecules)' from its R&D portfolio.
The real payoffs from new molecules were expected to occur only after three to four years. Meanwhile, the company would have to pare operational costs, work at re-establishing and growing the revenue base it lost in 2004-05, he said.
